| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 14 | 2022 | 255 | 4.480 |
Why?
|
| Genetic Predisposition to Disease | 35 | 2023 | 368 | 3.180 |
Why?
|
| Colorectal Neoplasms | 24 | 2023 | 613 | 2.650 |
Why?
|
| Polymorphism, Single Nucleotide | 39 | 2023 | 373 | 2.030 |
Why?
|
| Early Detection of Cancer | 6 | 2022 | 501 | 1.550 |
Why?
|
| Polymorphism, Genetic | 11 | 2015 | 62 | 1.390 |
Why?
|
| Humans | 110 | 2023 | 17611 | 1.370 |
Why?
|
| Middle Aged | 71 | 2021 | 7911 | 1.340 |
Why?
|
| Breast Neoplasms | 12 | 2023 | 949 | 1.340 |
Why?
|
| Aged | 63 | 2021 | 6095 | 1.330 |
Why?
|
| Genome-Wide Association Study | 21 | 2023 | 243 | 1.330 |
Why?
|
| Case-Control Studies | 47 | 2022 | 1115 | 1.310 |
Why?
|
| Risk Factors | 56 | 2023 | 3325 | 1.260 |
Why?
|
| Biliary Tract Neoplasms | 14 | 2010 | 15 | 1.260 |
Why?
|
| Female | 81 | 2023 | 12608 | 1.220 |
Why?
|
| Prostatic Neoplasms | 11 | 2020 | 262 | 1.220 |
Why?
|
| Male | 73 | 2021 | 10008 | 1.190 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 142 | 1.100 |
Why?
|
| Fibrocystic Breast Disease | 4 | 2010 | 5 | 1.050 |
Why?
|
| Gallstones | 10 | 2010 | 14 | 0.910 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 205 | 0.900 |
Why?
|
| Adult | 51 | 2021 | 7598 | 0.880 |
Why?
|
| Molecular Epidemiology | 4 | 2021 | 44 | 0.840 |
Why?
|
| Genotype | 16 | 2021 | 227 | 0.750 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 19 | 0.710 |
Why?
|
| Smoking | 6 | 2020 | 483 | 0.700 |
Why?
|
| Patient Compliance | 2 | 2021 | 298 | 0.680 |
Why?
|
| Asian Continental Ancestry Group | 8 | 2020 | 90 | 0.650 |
Why?
|
| Decision Making | 1 | 2020 | 183 | 0.650 |
Why?
|
| Carcinoma | 2 | 2018 | 22 | 0.640 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 211 | 0.640 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 415 | 0.610 |
Why?
|
| Mendelian Randomization Analysis | 7 | 2021 | 24 | 0.600 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 375 | 0.590 |
Why?
|
| Ovarian Neoplasms | 3 | 2013 | 49 | 0.550 |
Why?
|
| Thyroid Neoplasms | 3 | 2019 | 11 | 0.540 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2011 | 75 | 0.540 |
Why?
|
| Quality Improvement | 3 | 2020 | 189 | 0.530 |
Why?
|
| Substance-Related Disorders | 3 | 2011 | 434 | 0.520 |
Why?
|
| China | 20 | 2010 | 130 | 0.520 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 1900 | 0.510 |
Why?
|
| Logistic Models | 10 | 2021 | 926 | 0.500 |
Why?
|
| Cohort Studies | 14 | 2021 | 2570 | 0.490 |
Why?
|
| Metformin | 1 | 2015 | 57 | 0.470 |
Why?
|
| Estrogen Receptor alpha | 2 | 2010 | 25 | 0.450 |
Why?
|
| MicroRNAs | 3 | 2017 | 16 | 0.440 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 8 | 0.440 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 268 | 0.410 |
Why?
|
| Cyclooxygenase 2 | 4 | 2020 | 6 | 0.400 |
Why?
|
| Incidence | 10 | 2020 | 1255 | 0.400 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2008 | 5 | 0.400 |
Why?
|
| State Medicine | 1 | 2011 | 6 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 748 | 0.390 |
Why?
|
| Efficiency, Organizational | 1 | 2011 | 32 | 0.390 |
Why?
|
| Carcinogenesis | 3 | 2020 | 9 | 0.380 |
Why?
|
| Alleles | 9 | 2020 | 84 | 0.380 |
Why?
|
| Risk Assessment | 10 | 2021 | 1097 | 0.380 |
Why?
|
| Health | 3 | 2015 | 33 | 0.370 |
Why?
|
| Receptors, Androgen | 1 | 2010 | 9 | 0.370 |
Why?
|
| Health Policy | 1 | 2011 | 122 | 0.360 |
Why?
|
| Testicular Neoplasms | 5 | 2008 | 11 | 0.360 |
Why?
|
| Sex Factors | 8 | 2021 | 643 | 0.360 |
Why?
|
| European Continental Ancestry Group | 9 | 2021 | 529 | 0.360 |
Why?
|
| Diet | 2 | 2021 | 365 | 0.350 |
Why?
|
| Breast Density | 2 | 2020 | 31 | 0.350 |
Why?
|
| Aspirin | 3 | 2021 | 63 | 0.350 |
Why?
|
| Aging | 3 | 2015 | 161 | 0.340 |
Why?
|
| Alcohol Drinking | 4 | 2022 | 368 | 0.340 |
Why?
|
| Population Surveillance | 6 | 2009 | 263 | 0.340 |
Why?
|
| Estradiol Dehydrogenases | 2 | 2008 | 2 | 0.330 |
Why?
|
| Liver Neoplasms | 3 | 2007 | 40 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 51 | 0.330 |
Why?
|
| Mass Screening | 5 | 2022 | 661 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2007 | 26 | 0.320 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2008 | 1 | 0.310 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 197 | 0.310 |
Why?
|
| Selenium | 2 | 2021 | 4 | 0.300 |
Why?
|
| Age Factors | 5 | 2021 | 917 | 0.300 |
Why?
|
| Risk | 8 | 2022 | 516 | 0.300 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 2 | 0.290 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 13 | 0.290 |
Why?
|
| Body Mass Index | 8 | 2023 | 958 | 0.290 |
Why?
|
| DNA Repair | 4 | 2017 | 10 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 50 | 0.290 |
Why?
|
| Gene Expression | 4 | 2022 | 23 | 0.280 |
Why?
|
| Folic Acid | 2 | 2022 | 32 | 0.280 |
Why?
|
| Retrospective Studies | 7 | 2020 | 2447 | 0.280 |
Why?
|
| Endometrial Neoplasms | 3 | 2014 | 35 | 0.280 |
Why?
|
| Ethnic Groups | 6 | 2020 | 485 | 0.280 |
Why?
|
| Membrane Proteins | 2 | 2006 | 38 | 0.270 |
Why?
|
| Neoplasms | 2 | 2022 | 438 | 0.270 |
Why?
|
| Nails | 1 | 2005 | 2 | 0.260 |
Why?
|
| Macular Degeneration | 2 | 2016 | 19 | 0.260 |
Why?
|
| Obesity | 7 | 2023 | 837 | 0.250 |
Why?
|
| Computational Biology | 2 | 2015 | 27 | 0.250 |
Why?
|
| Feces | 2 | 2020 | 80 | 0.240 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2008 | 5 | 0.240 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 16 | 0.230 |
Why?
|
| Multifactorial Inheritance | 2 | 2020 | 20 | 0.230 |
Why?
|
| United States | 9 | 2020 | 3956 | 0.230 |
Why?
|
| Genotyping Techniques | 3 | 2021 | 26 | 0.220 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 15 | 0.210 |
Why?
|
| Educational Status | 2 | 2020 | 200 | 0.210 |
Why?
|
| Watchful Waiting | 2 | 2019 | 18 | 0.210 |
Why?
|
| Transcriptome | 1 | 2023 | 22 | 0.210 |
Why?
|
| DNA-Binding Proteins | 4 | 2022 | 29 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2021 | 167 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 172 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2022 | 15 | 0.210 |
Why?
|
| Genetic Variation | 4 | 2017 | 77 | 0.210 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1309 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2022 | 32 | 0.210 |
Why?
|
| NF-kappa B | 2 | 2022 | 11 | 0.200 |
Why?
|
| Carcinoma, Papillary | 1 | 2002 | 3 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 65 | 0.200 |
Why?
|
| Salicylic Acid | 1 | 2021 | 1 | 0.200 |
Why?
|
| Bilirubin | 2 | 2020 | 30 | 0.200 |
Why?
|
| Genomics | 3 | 2020 | 55 | 0.200 |
Why?
|
| Reproductive History | 1 | 2002 | 17 | 0.200 |
Why?
|
| Mammography | 2 | 2020 | 169 | 0.200 |
Why?
|
| Menarche | 1 | 2002 | 28 | 0.200 |
Why?
|
| Micronutrients | 1 | 2021 | 9 | 0.190 |
Why?
|
| Health Care Costs | 2 | 2020 | 228 | 0.190 |
Why?
|
| Signal Transduction | 2 | 2018 | 30 | 0.190 |
Why?
|
| Smad7 Protein | 1 | 2021 | 2 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 30 | 0.190 |
Why?
|
| Metabolome | 1 | 2020 | 1 | 0.190 |
Why?
|
| Models, Genetic | 1 | 2020 | 23 | 0.180 |
Why?
|
| African Americans | 3 | 2020 | 472 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2020 | 4 | 0.180 |
Why?
|
| Counseling | 1 | 2022 | 189 | 0.180 |
Why?
|
| Genome, Human | 1 | 2020 | 32 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2020 | 6 | 0.180 |
Why?
|
| Fruit | 1 | 2020 | 79 | 0.180 |
Why?
|
| Dietary Fiber | 1 | 2020 | 59 | 0.180 |
Why?
|
| Vegetables | 1 | 2020 | 87 | 0.180 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 19 | 0.180 |
Why?
|
| Arachidonic Acid | 1 | 2020 | 1 | 0.180 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2020 | 5 | 0.180 |
Why?
|
| Family Health | 1 | 2010 | 44 | 0.180 |
Why?
|
| Adiposity | 1 | 2020 | 66 | 0.180 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2020 | 9 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2019 | 8 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2019 | 13 | 0.170 |
Why?
|
| Genetic Loci | 2 | 2017 | 55 | 0.170 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 20 | 0.170 |
Why?
|
| Return to Work | 1 | 2019 | 2 | 0.170 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 568 | 0.170 |
Why?
|
| Mandatory Programs | 1 | 2009 | 5 | 0.170 |
Why?
|
| Workplace | 1 | 2009 | 30 | 0.160 |
Why?
|
| Health Services | 1 | 2010 | 112 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 55 | 0.160 |
Why?
|
| Employment | 1 | 2009 | 42 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 3 | 2008 | 5 | 0.160 |
Why?
|
| Cytochrome P-450 CYP1A1 | 2 | 2009 | 6 | 0.160 |
Why?
|
| Women's Health | 1 | 2020 | 200 | 0.160 |
Why?
|
| Postmenopause | 1 | 2020 | 241 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 2 | 2017 | 75 | 0.160 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 34 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 201 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 4 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 3 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 289 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2019 | 17 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2017 | 1 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 2 | 0.150 |
Why?
|
| Oncogenes | 1 | 2017 | 1 | 0.150 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 1 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 9 | 0.150 |
Why?
|
| Mutation | 3 | 2023 | 128 | 0.150 |
Why?
|
| Body Size | 2 | 2008 | 31 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 2427 | 0.150 |
Why?
|
| Registries | 7 | 2019 | 471 | 0.140 |
Why?
|
| Breast | 3 | 2023 | 84 | 0.140 |
Why?
|
| Odds Ratio | 7 | 2010 | 671 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 155 | 0.140 |
Why?
|
| Haplotypes | 7 | 2015 | 34 | 0.140 |
Why?
|
| Adenoma | 1 | 2018 | 93 | 0.140 |
Why?
|
| Uterine Neoplasms | 2 | 2007 | 12 | 0.140 |
Why?
|
| Endometriosis | 2 | 2007 | 4 | 0.140 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 17 | 0.140 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 2 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 44 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2016 | 21 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 1210 | 0.130 |
Why?
|
| Telomere | 1 | 2015 | 19 | 0.130 |
Why?
|
| Phenotype | 3 | 2022 | 149 | 0.120 |
Why?
|
| California | 5 | 2020 | 2284 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2021 | 766 | 0.120 |
Why?
|
| Adolescent | 3 | 2020 | 3651 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 32 | 0.120 |
Why?
|
| Gene Frequency | 2 | 2017 | 43 | 0.110 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 4 | 0.110 |
Why?
|
| Prognosis | 4 | 2020 | 606 | 0.110 |
Why?
|
| Continental Population Groups | 1 | 2015 | 302 | 0.110 |
Why?
|
| Alcoholism | 1 | 2017 | 347 | 0.110 |
Why?
|
| Urban Population | 2 | 2005 | 116 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 91 | 0.100 |
Why?
|
| Ibuprofen | 1 | 2012 | 9 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 21 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 15 | 0.100 |
Why?
|
| Microsatellite Instability | 2 | 2023 | 16 | 0.100 |
Why?
|
| CpG Islands | 2 | 2023 | 22 | 0.100 |
Why?
|
| Gallbladder Neoplasms | 2 | 2010 | 3 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2023 | 41 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2010 | 428 | 0.100 |
Why?
|
| Inflammation | 2 | 2008 | 62 | 0.090 |
Why?
|
| beta Carotene | 1 | 2011 | 17 | 0.090 |
Why?
|
| Sex Characteristics | 2 | 2015 | 69 | 0.090 |
Why?
|
| Cyst Fluid | 1 | 2010 | 2 | 0.090 |
Why?
|
| Whole Exome Sequencing | 2 | 2022 | 8 | 0.090 |
Why?
|
| Parity | 2 | 2010 | 74 | 0.090 |
Why?
|
| Europe | 2 | 2020 | 42 | 0.090 |
Why?
|
| Cholelithiasis | 2 | 2007 | 2 | 0.090 |
Why?
|
| Liver Cirrhosis | 2 | 2007 | 35 | 0.090 |
Why?
|
| Seminoma | 2 | 2007 | 3 | 0.090 |
Why?
|
| Reproduction | 1 | 2010 | 12 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 10 | 0.090 |
Why?
|
| Asian Americans | 2 | 2008 | 176 | 0.090 |
Why?
|
| Datasets as Topic | 2 | 2020 | 17 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 31 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 53 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 15 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1267 | 0.080 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 36 | 0.080 |
Why?
|
| Lipids | 1 | 2009 | 77 | 0.080 |
Why?
|
| Age Distribution | 3 | 2008 | 246 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2007 | 12 | 0.080 |
Why?
|
| Hormones | 1 | 2009 | 14 | 0.080 |
Why?
|
| Aromatase | 1 | 2008 | 7 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 4 | 0.080 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 6 | 0.080 |
Why?
|
| Lymphoma | 1 | 2008 | 6 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 6 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 13 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 27 | 0.080 |
Why?
|
| SEER Program | 1 | 2008 | 91 | 0.080 |
Why?
|
| Biliary Tract | 1 | 2007 | 2 | 0.080 |
Why?
|
| Genetic Pleiotropy | 2 | 2020 | 9 | 0.080 |
Why?
|
| Body Height | 1 | 2008 | 62 | 0.070 |
Why?
|
| Guaiac | 1 | 2007 | 3 | 0.070 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2007 | 2 | 0.070 |
Why?
|
| Immunochemistry | 1 | 2007 | 18 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 1 | 2007 | 24 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 260 | 0.070 |
Why?
|
| Feeding Behavior | 2 | 2006 | 166 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 4 | 0.070 |
Why?
|
| Liver | 1 | 2007 | 32 | 0.070 |
Why?
|
| Fertility | 1 | 2007 | 8 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2007 | 1 | 0.070 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 1 | 0.070 |
Why?
|
| Denmark | 4 | 2007 | 18 | 0.070 |
Why?
|
| Insulin | 1 | 2008 | 205 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2007 | 23 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 80 | 0.070 |
Why?
|
| Dairy Products | 1 | 2006 | 22 | 0.070 |
Why?
|
| Interviews as Topic | 4 | 2009 | 305 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2006 | 51 | 0.070 |
Why?
|
| Tea | 1 | 2006 | 8 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2006 | 34 | 0.070 |
Why?
|
| Occult Blood | 1 | 2007 | 153 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2005 | 8 | 0.070 |
Why?
|
| Puberty | 1 | 2006 | 58 | 0.070 |
Why?
|
| DNA Glycosylases | 1 | 2005 | 5 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2006 | 237 | 0.060 |
Why?
|
| Hepatitis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Leiomyoma | 1 | 2005 | 12 | 0.060 |
Why?
|
| Mothers | 1 | 2006 | 105 | 0.060 |
Why?
|
| Occupations | 1 | 2005 | 16 | 0.060 |
Why?
|
| Colposcopy | 1 | 2005 | 4 | 0.060 |
Why?
|
| Cervix Uteri | 1 | 2005 | 5 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2017 | 72 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2017 | 1259 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 304 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 7 | 0.060 |
Why?
|
| San Francisco | 2 | 2002 | 64 | 0.060 |
Why?
|
| Adenomatous Polyps | 1 | 2005 | 15 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 48 | 0.060 |
Why?
|
| Tissue Preservation | 1 | 2004 | 1 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 351 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2008 | 154 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 119 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2010 | 177 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2019 | 681 | 0.050 |
Why?
|
| Colonoscopy | 2 | 2020 | 251 | 0.050 |
Why?
|
| Exome | 1 | 2022 | 21 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2022 | 2 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2016 | 30 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 709 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2002 | 26 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 91 | 0.050 |
Why?
|
| Plants | 1 | 2001 | 2 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2001 | 3 | 0.050 |
Why?
|
| Isoflavones | 1 | 2001 | 14 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 105 | 0.050 |
Why?
|
| Thorax | 1 | 2021 | 5 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2021 | 15 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 23 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2020 | 23 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 1 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 62 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 3 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 2020 | 4 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2020 | 12 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2021 | 87 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2020 | 44 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 1 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 1 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2020 | 1 | 0.040 |
Why?
|
| Voltage-Gated Sodium Channel beta-1 Subunit | 1 | 2020 | 1 | 0.040 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2020 | 1 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 9 | 0.040 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2020 | 3 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 70 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 197 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2019 | 3 | 0.040 |
Why?
|
| Protective Factors | 1 | 2020 | 32 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 7 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 19 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 30 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 101 | 0.040 |
Why?
|
| Social Class | 1 | 2020 | 120 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 35 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 79 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 29 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 6 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 106 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 2 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 218 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 6 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 5 | 0.040 |
Why?
|
| Family | 1 | 2010 | 111 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 28 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 85 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 186 | 0.040 |
Why?
|
| Hispanic Americans | 2 | 2017 | 404 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 5 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2020 | 193 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 318 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2019 | 83 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 325 | 0.040 |
Why?
|
| Introns | 2 | 2008 | 9 | 0.040 |
Why?
|
| Health Status | 1 | 2010 | 298 | 0.040 |
Why?
|
| Homozygote | 1 | 2017 | 13 | 0.040 |
Why?
|
| Life Style | 1 | 2019 | 332 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 309 | 0.040 |
Why?
|
| Korea | 2 | 2008 | 9 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2017 | 12 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 4 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2017 | 5 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 129 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2008 | 297 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2017 | 215 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 264 | 0.040 |
Why?
|
| Prostate | 1 | 2017 | 28 | 0.040 |
Why?
|
| Carboplatin | 1 | 2016 | 7 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 8 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2016 | 9 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2017 | 162 | 0.030 |
Why?
|
| Poland | 2 | 2007 | 3 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 9 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 45 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 251 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 60 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 14 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 18 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 381 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 531 | 0.030 |
Why?
|
| Child | 1 | 2010 | 2474 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 12 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 20 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 27 | 0.030 |
Why?
|
| Pregnancy | 2 | 2010 | 1494 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 78 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 884 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 108 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2011 | 1 | 0.020 |
Why?
|
| DNA Ligase ATP | 1 | 2011 | 2 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2011 | 2 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 4 | 0.020 |
Why?
|
| Endonucleases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 11 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2011 | 19 | 0.020 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2009 | 8 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 101 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 9 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2009 | 12 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 22 | 0.020 |
Why?
|
| Breast Self-Examination | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cyclin H | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 2 | 0.020 |
Why?
|
| Japan | 1 | 2008 | 14 | 0.020 |
Why?
|
| Philippines | 1 | 2008 | 22 | 0.020 |
Why?
|
| Vietnam | 1 | 2008 | 33 | 0.020 |
Why?
|
| Hydro-Lyases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Peroxisomal Multifunctional Protein-2 | 1 | 2008 | 1 | 0.020 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2008 | 3 | 0.020 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2008 | 1 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2008 | 2 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2008 | 10 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 20 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2007 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2007 | 15 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 5 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 2 | 0.020 |
Why?
|
| Gallbladder Diseases | 1 | 2007 | 2 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2007 | 1 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2007 | 2 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 8 | 0.020 |
Why?
|
| Somatomedins | 1 | 2007 | 5 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2007 | 14 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cholesterol | 1 | 2007 | 106 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 17 | 0.020 |
Why?
|
| Leptin | 1 | 2007 | 29 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2007 | 65 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 21 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 49 | 0.020 |
Why?
|
| Cholangitis | 1 | 2007 | 1 | 0.020 |
Why?
|
| Cholecystolithiasis | 1 | 2007 | 1 | 0.020 |
Why?
|
| Choledocholithiasis | 1 | 2007 | 1 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 5 | 0.020 |
Why?
|
| Lymphotoxin-alpha | 1 | 2007 | 2 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2007 | 17 | 0.020 |
Why?
|
| Maryland | 1 | 2006 | 16 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2007 | 42 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2006 | 2 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2006 | 13 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2006 | 25 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2006 | 81 | 0.020 |
Why?
|
| Mortality | 1 | 2006 | 117 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2006 | 116 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2006 | 114 | 0.020 |
Why?
|
| Artifacts | 1 | 2005 | 3 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2005 | 12 | 0.020 |
Why?
|
| Biopsy | 1 | 2005 | 74 | 0.020 |
Why?
|
| Heterozygote | 1 | 2005 | 26 | 0.020 |
Why?
|
| Iron | 1 | 2005 | 16 | 0.020 |
Why?
|
| Algorithms | 1 | 2006 | 233 | 0.020 |
Why?
|
| Epitopes | 1 | 2004 | 4 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 5 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2004 | 12 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 374 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 44 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 50 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 46 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 51 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1086 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 487 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 500 | 0.010 |
Why?
|
| Phytoestrogens | 1 | 2001 | 7 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2001 | 5 | 0.010 |
Why?
|